FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH (CDER)

October 20, 2005

Pediatric Oncology Subcommittee of the Oncology Drugs Advisory Committee Meeting

Advisors and Consultants Conference Room, #1066, Rockville, Maryland

Questions to the Subcommittee

Regarding required postmarketing studies as a condition of accelerated approval for clofarabine:

1. Are the proposed patient populations (ALL, first or second relapse) and primary efficacy endpoint (4 month EFS) feasible and will the design permit an adequate assessment of clofarabine's clinical benefit?

2. To what extent can the data generated in adult patients with relapsed/refractory AML support efficacy in pediatric patients with ALL?

Regarding pegfilgrastim postmarketing requirements under PREA:

3. Please comment on Amgen's ongoing study in patients with sarcoma treated with VAdriac/IE. Will this study allow for extrapolation of activity and safety findings across all age groups and to different pediatric cancers?

Regarding palifermin postmarketing requirements under PREA:

4. Please comment on the the suitability and feasibility of the proposed pediatric program; specifically: need for dose escalation, need for collection of pharmacokinetic data, choice of patient population (homogenous vs heterogenous with regard to underlying disease, source of stem cells, cytotoxic regimen, etc.)

Regarding ongoing studies of vincristine/actinomycin-D

5. Please comment on the approach to the generation of safety/efficacy and pharmacokinetic information on vincristine and actinomycin-D. Does the subcommittee have suggestions about additional data that should be collected?

Regarding the off- patent BPCA process:

6. Please discuss additional off-patent drugs (and/or therapeutic drug classes) used in pediatric patients with malignancies for which additional data in labeling could provide health benefits.